Estabrook Capital Management continued to hold its position in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,559 shares of the medical equipment provider’s stock at the end of the 2nd quarter. Estabrook Capital Management’s holdings in Boston Scientific Corporation were worth $126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Bronfman E.L. Rothschild L.P. increased its holdings in Boston Scientific Corporation by 7.2% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after purchasing an additional 338 shares in the last quarter. Guardian Life Insurance Co. of America increased its holdings in Boston Scientific Corporation by 0.9% during the 1st quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 49 shares in the last quarter. Peddock Capital Advisors LLC bought a new position in Boston Scientific Corporation during the 2nd quarter worth about $201,000. Parametrica Management Ltd bought a new position in Boston Scientific Corporation during the 2nd quarter worth about $219,000. Finally, Commerce Bank bought a new position in Boston Scientific Corporation during the 1st quarter worth about $207,000. Institutional investors and hedge funds own 90.52% of the company’s stock.

A number of equities analysts have issued reports on the company. Jefferies Group LLC reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Thursday. Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a report on Friday, September 1st. BidaskClub cut Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. Finally, UBS AG reiterated a “buy” rating and set a $31.00 target price (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $29.88.

In other Boston Scientific Corporation news, SVP Maulik Nanavaty sold 27,031 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $27.08, for a total value of $731,999.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $28.02, for a total transaction of $434,310.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 275,257 shares of company stock valued at $7,512,394. 0.74% of the stock is currently owned by insiders.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.88% during midday trading on Friday, reaching $28.79. 5,336,185 shares of the company traded hands. The firm has a market capitalization of $39.50 billion, a PE ratio of 51.50 and a beta of 1.09. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $29.08. The company has a 50-day moving average of $27.06 and a 200 day moving average of $26.38.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 earnings per share. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Estabrook Capital Management Has $126,000 Holdings in Boston Scientific Corporation (BSX)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/10/estabrook-capital-management-has-126000-holdings-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.